Literature DB >> 26108139

Management of Noncardiac Comorbidities in Chronic Heart Failure.

Vun Heng Chong1, Jagdeep Singh2, Helen Parry1, Jocelyn Saunders3, Farhad Chowdhury3, Donna M Mancini4, Chim C Lang1.   

Abstract

Prevalence of heart failure is increasing, especially in the elderly population. Noncardiac comorbidities complicate heart failure care and are increasingly common in elderly patients with reduced or preserved ejection fraction heart failure, owing to prolongation of patient's lives by advances in chronic heart failure (CHF) management. Common comorbidities include respiratory disease, renal dysfunction, anemia, arthritis, obesity, diabetes mellitus, cognitive dysfunction, and depression. These conditions contribute to the progression of the disease and may alter the response to treatment, partly as polypharmacy is inevitable in these patients. Cardiologists and other physicians caring for patients with CHF need to be vigilant to comorbid conditions that complicate the care of these patients. There is now more guidance on management of noncardiac comorbidities in heart failure, and this article contains a comprehensive review of the most recent updates on management of noncardiac comorbidities in CHF.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  Comorbidities; Drug treatment; Heart failure; Management

Mesh:

Year:  2015        PMID: 26108139     DOI: 10.1111/1755-5922.12141

Source DB:  PubMed          Journal:  Cardiovasc Ther        ISSN: 1755-5914            Impact factor:   3.023


  8 in total

Review 1.  Role of the Pharmacist for Improving Self-care and Outcomes in Heart Failure.

Authors:  Daya Ram Parajuli; Julie Franzon; Ross A McKinnon; Sepehr Shakib; Robyn A Clark
Journal:  Curr Heart Fail Rep       Date:  2017-04

2.  Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece.

Authors:  Kostas Athanasakis; Aikaterini Bilitou; Dawn Lee; Eleftheria Karampli; Apostolos Karavidas; John Parissis; Georgia Sykara; John Kyriopoulos
Journal:  Clinicoecon Outcomes Res       Date:  2016-10-12

Review 3.  Establishing a pragmatic framework to optimise health outcomes in heart failure and multimorbidity (ARISE-HF): A multidisciplinary position statement.

Authors:  Simon Stewart; Barbara Riegel; Cynthia Boyd; Yasmin Ahamed; David R Thompson; Louise M Burrell; Melinda J Carrington; Andrew Coats; Bradi B Granger; Julie Hides; William S Weintraub; Debra K Moser; Victoria Vaughan Dickson; Cressida J McDermott; Ashley K Keates; Michael W Rich
Journal:  Int J Cardiol       Date:  2016-03-10       Impact factor: 4.164

4.  Prevalence and determinants of Hyperpolypharmacy in adults with heart failure: an observational study from the National Health and Nutrition Examination Survey (NHANES).

Authors:  Peter J Kennel; Jerard Kneifati-Hayek; Joanna Bryan; Samprit Banerjee; Irina Sobol; Mark S Lachs; Monika M Safford; Parag Goyal
Journal:  BMC Cardiovasc Disord       Date:  2019-04-01       Impact factor: 2.298

5.  Antidepressant Prescribing Patterns in Heart Failure Patients at Residential Aged Care Facilities in Australia: A Cross-sectional Study.

Authors:  Ruba A M Marashdeh; Richard Parsons; Tin Fei Sim
Journal:  J Res Pharm Pract       Date:  2019 Apr-Jun

6.  Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design.

Authors:  Jagdeep S S Singh; Amir Fathi; Keeran Vickneson; Ify Mordi; Mohapradeep Mohan; J Graeme Houston; Ewan R Pearson; Allan D Struthers; Chim C Lang
Journal:  Cardiovasc Diabetol       Date:  2016-07-15       Impact factor: 9.951

7.  Identifying the needs for competency-based education in Europe: a needs assessment of cardiologists across 52 countries.

Authors:  S Murray; C Carrera; P Lazure; P Vardas; J L Zamorano; P Kearney; L Goncalves; K Fox; A Vahanian
Journal:  J Eur CME       Date:  2017-06-22

8.  Association of Obesity With Severity of Heart Failure Exacerbation: A Population-Based Study.

Authors:  Atsushi Hirayama; Tadahiro Goto; Yuichi J Shimada; Mohammad Kamal Faridi; Carlos A Camargo; Kohei Hasegawa
Journal:  J Am Heart Assoc       Date:  2018-03-15       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.